Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC

ABSTRACT The pharmacokinetics of regorafenib and its active metabolites, M2 and M5, vary widely among individual patients. However, the relationship between these plasma concentrations and therapeutic efficacy remains unclear. Patients with metastatic colorectal cancer (mCRC) receiving regorafenib a...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Kazuo Kobayashi, Takeru Wakatsuki, Erika Sugiyama, Eiji. Shinozaki, Masataka Tajima, Mariko Ogura, Keisho Chin, Akira Ooki, Hiroki Osumi, Shota Fukuoka, Shohei Udagawa, Keitaro Shimozaki, Takeshi Aoyama, Yasuhiro Nakano, Kazuyoshi Kawakami, Wataru Suzuki, Takashi Yokokawa, Hitoshi Sato, Masakazu Yamaguchi, Kensei Yamaguchi
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wiley 2025-11-01
סדרה:	Clinical and Translational Science
נושאים:	neutrophil to lymphocyte ratio pharmacokinetics polymorphisms progression‐free survival regorafenib
גישה מקוונת:	https://doi.org/10.1111/cts.70386
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!